<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39340558</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1432-1335</ISSN><JournalIssue CitedMedium="Internet"><Volume>150</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>28</Day></PubDate></JournalIssue><Title>Journal of cancer research and clinical oncology</Title><ISOAbbreviation>J Cancer Res Clin Oncol</ISOAbbreviation></Journal><ArticleTitle>Transient MRI changes and neurological deterioration in glioblastoma upon SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>437</StartPage><MedlinePgn>437</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">437</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00432-024-05963-4</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Little is known about the effect of SARS-CoV-2 infection on glioblastoma (GBM) growth, metabolism, and prognosis. Immunological changes within GBM tissue are potentially symptomatic, underlining the urgent need for a better understanding of this phenomenon. To date, the complex underlying biology has not been fully elucidated. A decisive role of the tumor microenvironment (TME) and the components of the immune system acting within it is assumed.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Immunohistochemical staining of SARS-CoV-2 spike protein and immune cell infiltration of TME was performed on the tumor tissue of one patient. This patient developed hemiparesis 14 days after symptomatic SARS-CoV-2 infection, leading to tumor diagnosis. Subsequently and after biopsy, there was an unexpectedly good response to chemotherapy only. In looking for further evidence of the potential of SARS-CoV-2 to influence the course of GBM, two additional adult patients that had transient MRI changes and neurological deterioration following SARS-CoV-2 infection were evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the patient for whom neurological deterioration in the course of SARS-CoV-2 led to GBM diagnosis, immunohistochemistry revealed virus-specific protein accumulation in the tumor cells, microglial activation, and the formation of T-cell nodules. In the other two patients, the findings were compatible with symptomatic pseudoprogression that occurred in a temporal relationship with SARS-CoV-2 infection.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results indicate a possible association between clinically relevant changes in GBM biology and SARS-CoV-2 infection, with histological confirmation of SARS-CoV-2-associated changes within the tumor tissue. The exact pathomechanism and underlying inflammatory pathways require further investigation.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zeyen</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurooncology, Center for Neurology, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Friker</LastName><ForeName>Lea L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Experimental Oncology, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paech</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neuroradiology, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schaefer</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurooncology, Center for Neurology, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weller</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurooncology, Center for Neurology, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Vascular Neurology, Center for Neurology, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zschernack</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Layer</LastName><ForeName>Julian P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Institute of Experimental Oncology, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Potthoff</LastName><ForeName>Anna-Laura</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernhardt</LastName><ForeName>Marit</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Pathology, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanders</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Pathology, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kristiansen</LastName><ForeName>Glen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Pathology, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoelzel</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Experimental Oncology, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gkika</LastName><ForeName>Eleni</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radbruch</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroradiology, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pietsch</LastName><ForeName>Torsten</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrlinger</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Neurooncology, Center for Neurology, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schaub</LastName><ForeName>Christina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5257-4183</Identifier><AffiliationInfo><Affiliation>Department of Neurooncology, Center for Neurology, University Hospital Bonn, Bonn, Germany. ch.schaubcs@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Cancer Res Clin Oncol</MedlineTA><NlmUniqueID>7902060</NlmUniqueID><ISSNLinking>0171-5216</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005909" MajorTopicYN="Y">Glioblastoma</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001932" MajorTopicYN="Y">Brain Neoplasms</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Glioblastoma</Keyword><Keyword MajorTopicYN="N">MRI</Keyword><Keyword MajorTopicYN="N">Pseudoprogression</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Tumor microenvironment</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>11</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340558</ArticleId><ArticleId IdType="pmc">PMC11438616</ArticleId><ArticleId IdType="doi">10.1007/s00432-024-05963-4</ArticleId><ArticleId IdType="pii">10.1007/s00432-024-05963-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bauer L, van Riel D (2023) Do SARS-CoV-2 variants Differ in their neuropathogenicity? MBio. 14(1):e0292022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9973339</ArticleId><ArticleId IdType="pubmed">36651750</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer L, Rissmann M, Benavides FFW, Leijten L, van Run P, Begeman L et al (2022) In vitro and in vivo differences in neurovirulence between D614G, Delta and Omicron BA.1 SARS-CoV-2 variants. Acta Neuropathol Commun 10(1):124</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9441226</ArticleId><ArticleId IdType="pubmed">36058935</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendella Z, Widmann CN, Layer JP, Layer YL, Haase R, Sauer M et al (2023) Brain volume changes after COVID-19 compared to healthy controls by Artificial Intelligence-based MRI volumetry. Diagnostics (Basel). 13(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10216908</ArticleId><ArticleId IdType="pubmed">37238200</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y-R, Ugiliweneza B, Burton E, Woo SY, Boakye M, Skirboll S (2017) The effect of postoperative infection on survival in patients with glioblastoma. J Neurosurg 127(4):807–811</Citation><ArticleIdList><ArticleId IdType="pubmed">27935360</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722</Citation><ArticleIdList><ArticleId IdType="pubmed">24552318</ArticleId></ArticleIdList></Reference><Reference><Citation>Desjardins A, Gromeier M, Herndon JE, Beaubier N, Bolognesi DP, Friedman AH et al (2018) Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 379(2):150–161</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6065102</ArticleId><ArticleId IdType="pubmed">29943666</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellingson BM, Chung C, Pope WB, Boxerman JL, Kaufmann TJ (2017) Pseudoprogression, radionecrosis, inflammation or true tumor progression? Challenges associated with Glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol 134(3):495–504</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7893814</ArticleId><ArticleId IdType="pubmed">28382534</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman GK, Johnston JM, Bag AK, Bernstock JD, Li R, Aban I et al (2021) Oncolytic HSV-1 G207 immunovirotherapy for Pediatric High-Grade Gliomas. N Engl J Med 384(17):1613–1622</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8284840</ArticleId><ArticleId IdType="pubmed">33838625</ArticleId></ArticleIdList></Reference><Reference><Citation>Friendlander AH, Ettinger RL (2009) Karnofsky performance status scale. Spec Care Dentist 29(4):147–148</Citation><ArticleIdList><ArticleId IdType="pubmed">19573040</ArticleId></ArticleIdList></Reference><Reference><Citation>Galldiks N, Kocher M, Langen K-J (2017) Pseudoprogression after glioma therapy: an update. Expert Rev Neurother 17(11):1109–1115</Citation><ArticleIdList><ArticleId IdType="pubmed">28862482</ArticleId></ArticleIdList></Reference><Reference><Citation>Gállego Pérez-Larraya J, Garcia-Moure M, Labiano S, Patiño-García A, Dobbs J, Gonzalez-Huarriz M et al (2022) Oncolytic DNX-2401 Virus for Pediatric diffuse intrinsic pontine glioma. N Engl J Med 386(26):2471–2481</Citation><ArticleIdList><ArticleId IdType="pubmed">35767439</ArticleId></ArticleIdList></Reference><Reference><Citation>Goerig NL, Frey B, Korn K, Fleckenstein B, Überla K, Schmidt MA et al (2016) Frequent occurrence of therapeutically reversible CMV-associated encephalopathy during radiotherapy of the brain. Neuro Oncol 18(12):1664–1672</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5793811</ArticleId><ArticleId IdType="pubmed">27286796</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory TA, Knight SR, Aaroe AE, Highsmith KN, Janatpour ZC, O’Brien BJ et al (2024) Accelerated tumor progression after COVID-19 infection in patients with glioblastoma: a retrospective case-control study. Neurooncol Pract 11(4):475–483</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11241387</ArticleId><ArticleId IdType="pubmed">39006516</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M et al (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 393(10172):678–688</Citation><ArticleIdList><ArticleId IdType="pubmed">30782343</ArticleId></ArticleIdList></Reference><Reference><Citation>Hounchonou HF, Bajgora G, Esmaeilzadeh M, Hartmann C, Krauss JK (2024) Surgical site infections after glioblastoma surgery: boon or bane? J Cancer Res Clin Oncol 150(2):36</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10817840</ArticleId><ArticleId IdType="pubmed">38279060</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS et al (2018) Phase I study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol 36(14):1419–1427</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6075856</ArticleId><ArticleId IdType="pubmed">29432077</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Fèvre C, Lhermitte B, Ahle G, Chambrelant I, Cebula H, Antoni D et al (2021) Pseudoprogression versus true progression in glioblastoma patients: a multiapproach literature review: part 1 - Molecular, morphological and clinical features. Crit Rev Oncol Hematol 157:103188</Citation><ArticleIdList><ArticleId IdType="pubmed">33307200</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, Liu C, Hu A, Zhang D, Yang H, Mao Y (2024) Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives. J Hematol Oncol 17(1):31. 10.1186/s13045-024-01544-7. Published 2024 May 8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11077829</ArticleId><ArticleId IdType="pubmed">38720342</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling AL, Solomon IH, Landivar AM, Nakashima H, Woods JK, Santos A et al (2023) Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature 623(7985):157–166</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620094</ArticleId><ArticleId IdType="pubmed">37853118</ArticleId></ArticleIdList></Reference><Reference><Citation>Look T, Puca E, Bühler M et al (2023) Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell-dependent regression of glioblastoma. Sci Transl Med 15(697):eadf2281. 10.1126/scitranslmed.adf2281</Citation><ArticleIdList><ArticleId IdType="pubmed">37224228</ArticleId></ArticleIdList></Reference><Reference><Citation>Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231-1251. 10.1093/neuonc/noab106</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8328013</ArticleId><ArticleId IdType="pubmed">34185076</ArticleId></ArticleIdList></Reference><Reference><Citation>Melguizo-Gavilanes I, Bruner JM, Guha-Thakurta N, Hess KR, Puduvalli VK (2015) Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard? J Neurooncol 123(1):141–150</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4780341</ArticleId><ArticleId IdType="pubmed">25894594</ArticleId></ArticleIdList></Reference><Reference><Citation>Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU et al (2017) The neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol 19(5):625–635</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5464449</ArticleId><ArticleId IdType="pubmed">28453751</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C et al (2017) Short-course Radiation plus Temozolomide in Elderly patients with Glioblastoma. N Engl J Med 376(11):1027–1037</Citation><ArticleIdList><ArticleId IdType="pubmed">28296618</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwabenland M, Salié H, Tanevski J, Killmer S, Lago MS, Schlaak AE et al (2021) Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions. Immunity 54(7):1594–1610e11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8188302</ArticleId><ArticleId IdType="pubmed">34174183</ArticleId></ArticleIdList></Reference><Reference><Citation>Solár P, Mackerle Z, Hendrych M, Pospisil P, Lakomy R, Valekova H et al (2022) Prolonged survival in patients with local chronic infection after high-grade glioma treatment: two case reports. Front Oncol 12:1073036</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9800515</ArticleId><ArticleId IdType="pubmed">36591464</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez-Meade P, Watanabe F, Ruiz-Garcia H, Rafferty SB, Moniz-Garcia D, Schiapparelli PV et al (2023) SARS-CoV2 entry factors are expressed in primary human glioblastoma and recapitulated in cerebral organoid models. J Neurooncol 161(1):67–76</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9808689</ArticleId><ArticleId IdType="pubmed">36595192</ArticleId></ArticleIdList></Reference><Reference><Citation>Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J et al (2022) Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. Nat Med 28(8):1630–1639</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388376</ArticleId><ArticleId IdType="pubmed">35864254</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel MME, Wagner A, Gempt J, Krenzlin H, Zeyen T, Drexler R et al (2023) Impact of the SARS-CoV-2 pandemic on the survival of patients with high-grade glioma and best practice recommendations. Sci Rep 13(1):2766</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9933015</ArticleId><ArticleId IdType="pubmed">36797335</ArticleId></ArticleIdList></Reference><Reference><Citation>Wick W, Chinot OL, Bendszus M, Mason W, Henriksson R, Saran F et al (2016) Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Neuro Oncol 18(10):1434–1441</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5035525</ArticleId><ArticleId IdType="pubmed">27515827</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Liu D, Fang S, Ma W, Wang Y (2022) Cytomegalovirus and glioblastoma: a review of the biological associations and therapeutic strategies. J Clin Med 11:17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9457369</ArticleId><ArticleId IdType="pubmed">36079151</ArticleId></ArticleIdList></Reference><Reference><Citation>Young JS, Al-Adli N, Scotford K, Cha S, Berger MS (2023) Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know. J Neurosurg 139(3):748–759</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10412732</ArticleId><ArticleId IdType="pubmed">36790010</ArticleId></ArticleIdList></Reference><Reference><Citation>Youssef G, Wen PY (2024) Updated Response Assessment in Neuro-Oncology (RANO) for gliomas. Curr Neurol Neurosci Rep 24(2):17–25</Citation><ArticleIdList><ArticleId IdType="pubmed">38170429</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Wang Y, Wang Y, Xiao H, Chen X, Lei Y et al (2022) Perfusion magnetic resonance imaging in the differentiation between glioma recurrence and pseudoprogression: a systematic review, meta-analysis and meta-regression. Quant Imaging Med Surg 12(10):4805–4822</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9511424</ArticleId><ArticleId IdType="pubmed">36185045</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>